Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 15/01/2018 |
| Rapid review completed | 14/02/2018 |
| Rapid Review outcome | Full pharamcoeconomic assessment recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations; April 2019